Yasmin was introduced in 2001 by Berlex Laboratories as a combined hormonal oral contraceptive. After Berlex was acquired by Bayer Healthcare in 2006, they marketed Yaz, which was an identical drug to Yasmin, except that Yasmin contained 30 mcg of ethinyl estradiol, while Yaz contained 20 mcg. Yasmin/Yaz was sold throughout the world but they are linked with problems and side effects.
Side effects such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), heart attack, stroke and death were prevalent among women who used Yasmin/Yaz. These problems were linked to drospirenone, which acts as a diuretic related to spironolactone. This causes high potassium levels, called hyperkalemia, which results in serious heart problems and other serious health issues.